Emmanuel A Asante

List of Publications by Year
in descending order

34 papers	2,368 citations	331670 21 h-index	377865 34 g-index
34 all docs	34 docs citations	34 times ranked	2159 citing authors

#	Article	IF	Citations
1	Humanized Transgenic Mice Are Resistant to Chronic Wasting Disease Prions From Norwegian Reindeer and Moose. Journal of Infectious Diseases, 2022, 226, 933-937.	4.0	25
2	Spontaneous generation of prions and transmissible PrP amyloid in a humanised transgenic mouse model of A117V GSS. PLoS Biology, 2020, 18, e3000725.	5.6	13
3	Experimental sheep BSE prions generate the vCJD phenotype when serially passaged in transgenic mice expressing human prion protein. Journal of the Neurological Sciences, 2018, 386, 4-11.	0.6	6
4	Protective Effect of Val₁₂₉-PrP against Bovine Spongiform Encephalopathy but not Variant Creutzfeldt-Jakob Disease. Emerging Infectious Diseases, 2017, 23, 1522-1530.	4.3	26
5	Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. Acta Neuropathologica, 2015, 130, 511-523.	7.7	79
6	Transmission Properties of Human PrP 102L Prions Challenge the Relevance of Mouse Models of GSS. PLoS Pathogens, 2015, 11, e1004953.	4.7	27
7	A naturally occurring variant of the human prion protein completely prevents prion disease. Nature, 2015, 522, 478-481.	27.8	144
8	Atypical Scrapie Prions from Sheep and Lack of Disease in Transgenic Mice Overexpressing Human Prion Protein. Emerging Infectious Diseases, 2013, 19, 1731-1739.	4.3	27
9	Inherited Prion Disease A117V Is Not Simply a Proteinopathy but Produces Prions Transmissible to Transgenic Mice Expressing Homologous Prion Protein. PLoS Pathogens, 2013, 9, e1003643.	4.7	46
10	Overexpression of the Hspa13 (Stch) gene reduces prion disease incubation time in mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13722-13727.	7.1	21
11	Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain, 2012, 135, 819-832.	7.6	97
12	Threshold for epileptiform activity is elevated in prion knockout mice. Neuroscience, 2011, 179, 56-61.	2.3	22
13	Effect of fixation on brain and lymphoreticular vCJD prions and bioassay of key positive specimens from a retrospective vCJD prevalence study. Journal of Pathology, 2011, 223, 511-518.	4.5	22
14	Interaction between prion protein and toxic amyloid Î² assemblies can be therapeutically targeted at multiple sites. Nature Communications, 2011, 2, 336.	12.8	263
15	Review: Contribution of transgenic models to understanding human prion disease. Neuropathology and Applied Neurobiology, 2010, 36, 576-597.	3.2	59
16	Chronic wasting disease prions are not transmissible to transgenic mice overexpressing human prion protein. Journal of General Virology, 2010, 91, 2651-2657.	2.9	106
17	Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins. Journal of General Virology, 2009, 90, 546-558.	2.9	58
18	The origin of the prion agent of kuru: molecular and biological strain typing. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3747-3753.	4.0	39

#	Article	IF	Citations
19	Kuru prions and sporadic Creutzfeldtâ€“Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3885-3890.	7.1	62
20	Prion infectivity in variant Creutzfeldt-Jakob disease rectum. Gut, 2007, 56, 90-94.	12.1	28
21	RskÎ±-actin/hIGF-1 transgenic mice with increased IGF-I in skeletal muscle and blood: Impact on regeneration, denervation and muscular dystrophy. Growth Hormone and IGF Research, 2006, 16, 157-173.	1.1	19
22	Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein. Brain, 2006, 129, 1557-1569.	7.6	91
23	Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10759-10764.	7.1	68
24	Human Prion Protein with Valine 129 Prevents Expression of Variant CJD Phenotype. Science, 2004, 306, 1793-1796.	12.6	246
25	Pathogenic human prion protein rescues PrP null phenotype in transgenic mice. Neuroscience Letters, 2004, 360, 33-36.	2.1	14
26	Expression Pattern of a Mini Human PrP Gene Promoter in Transgenic Mice. Neurobiology of Disease, 2002, 10, 1-7.	4.4	15
27	BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO Journal, 2002, 21, 6358-6366.	7.8	317
28	Isolation and functional characterisation of the promoter region of the human prion protein gene. Gene, 2001, 268, 105-114.	2.2	43
29	Transgenic studies of the influence of the PrP structure on TSE diseases. Advances in Protein Chemistry, 2001, 57, 273-311.	4.4	8
30	Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature, 1995, 378, 779-783.	27.8	193
31	Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Human Molecular Genetics, 1995, 4, 1245-1250.	2.9	152
32	Tissue specific expression of an Î±-skeletal actin-lacZ fusion gene during development in transgenic mice. Transgenic Research, 1994, 3, 59-66.	2.4	13
33	Analysis of lines of mice selected for fat content: 3. Flux through the de novo lipid synthesis pathway. Genetical Research, 1991, 58, 123-127.	0.9	5
34	Analysis of lines of mice selected for fat content. 1. Correlated responses in the activities of NADPH-generating enzymes.. Genetical Research, 1989, 54, 155-160.	0.9	14